Commercialise your research? Aiming to start a company?
For researchers with entrepreneur aspirations.
TAKE PART IN THE VENTURE CHALLENGE!
The Health~Holland Venture Challenge is part of the LifeSciences@Work Startup Accelerator Programme. A dedicated team offers their expertise to life sciences researchers to translate inventions into viable business ideas.
In two 3-day workshops ‘competing’ teams will be challenged to translate their invention into a solid business case, to learn how to pitch and get valuable one-on-one coaching. At the end of the Challenge, the team with the best Venture Plan and pitch is awarded a prize of €25.000,-.
How it works: The Venture Challenge further explained.
Apply for the next edition: Venture-Proposal-Form-VC_Fall-2015
Conquest: winner of the Health~Holland Venture Challenge Spring 2015.
On June 4th, 2015 Conquest pitched together with 5 fellow Venture Challenge Teams during the SME Event organized by HollandBio. Conquest has developed a novel nanoparticle technology that provides unique multimodal imaging contrast. Conquest aims to create a revolution in diagnostic imaging. Conquest was represented by Mangala Srinivas, Erik Aarntzen and Frank Smeets of Radboudumc.
Need to set up clinical trails? How to find strategic partners?
For startup companies with growth ambitions.
APPLY FOR THE VALUE CENTRE VOUCHER!
As a starting entrepreneur in Life Sciences one faces multiple challenges. How to build a strong business case? This and other business related questions are welcomed by the Health~Holland Value Centre.
The Value Centre helps startup companies with growth ambitions. Core activities are focused to improve business cases and thereby accelerate market introduction or market expansion. Entrepreneurs can apply for a Value Centre Voucher to use on reimbursement issues, clinical trials, health technology assessment or finding funds etc.
Learn more about the Value Centre and how to ‘spent’ the Voucher .
First voucher for Inreda Diabetic
The start-up Inreda Diabetic is developing an artificial pancreas for diabetic patients. Inreda uses the Health Holland Value Centre voucher to perform a cost-effectiveness study of Inreda’s innovation. By doing so, Inreda is able to build a strong business model with a clear perspective on the costs and benefits of their innovation and how this relates to similar innovations. This information can be crucial for health insurance companies to reimburse the artificial pancreas.
Cristal Therapeutics Starts Clinical Phase I Trial with Nanomedicine CriPec® Docetaxel in Patients with Solid Tumours
Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel in patients with solid tumours.
Amgen to Aquire Privately-held Dezima Pharma
Amgen and Dezima Pharma B.V. (Dezima) announced that the companies have entered into a definitive acquisition agreement under which Amgen will acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. Dezima shareholders have approved the agreement.
MDxHealth Acquires NovioGendix to Expand Uro-Oncology Product Offering
MDxHealth SA (Euronext: MDXH.BR), announced that it has entered into an agreement to acquire NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer.
ONCODRONE Receives €2.5 Million EUROSTARS Grant
Oncodrone, the anti-cancer company based in Nijmegen, The Netherlands, has been granted a € 2,5 million Eurostars grant for the development of its lead drug OCD155 for treatment of prostate cancer.
SkylineDx appoints Leonard Kruimer as CFO Peter Schineller as CCO
SkylineDx, a molecular diagnostics company developing and commercializing innovative gene signature based diagnostics, announces the appointment of Leonard Kruimer as Chief Financial Officer per August 15th and Peter Schineller as Chief Commercial Officer per August 1st.
What startups want (from their accelerators): support, support and support – and maybe a bit of cash?
Read the findings of a study by Tech.eu what startups say about their accelerator experience.
Invitation! Become a partner of LS@W.
Help life sciences researchers to take their invention from the lab to the market.